Novartis' drug failure has negatively impacted Amgen's financial outlook.
2 reports, 2 independent
Updated Sep 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis' drug failure has negatively impacted Amgen's financial outlook.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Sub-event
Novartis drug failure impacts Amgen's outlook.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Novartis
Czech company
Nothing else this week.
Related events
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- Joint drug trial success boosts Amgen stock.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.